Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.
Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer – called glioblastoma, is 15 months. Less than five per cent of patients survive beyond five years.
HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumour samples and discovered that specialized immune cells in brain tumour patients are compromised. The researchers took this discovery and, in an animal model, identified a drug that is able to re-activate those immune cells and reduce brain tumour growth, thereby increasing the lifespan of mice two to three times. Their discovery will be published December 8th in the prestigious journal Nature Neuroscience.
Our brains normally contain specialized cells, called microglia, that defend against injury or infection. "Microglia are the brain's own dedicated immune system," explains Yong. "And in this study, we have formally demonstrated for the first time that these cells are compromised in living brain tumour patients."
As with other forms of cancer, brain tumours start as individual stem-like cells – called brain tumour initiating cells (BTICs). These cells quickly divide and grow, eventually forming a mass, or tumour. Yong and his team have discovered that the tumour disables microglia, permitting the rapid proliferation of BTICs, which ultimately leads to brain tumour growth.
"We refer to this as the battle for the brain, in which early on in the disease, the microglia are trying to destroy the brain tumour initiating cells," says Yong. "But over the course of time, the tumour disables the microglia and we start to see more initiating cells and more rapid tumour growth. We have sought to tip the battle in favour of the brain to suppress the tumour."
In addition to discovering this mechanism, Yong and Sarkar also identified a drug - amphotericin B (AmpB) - to reactivate microglia that in an animal model, showed a significant reduction in brain tumour growth.
"This drug was able to re-activate the disabled microglia," says Sarkar, "thus restoring the body's natural defense mechanisms and restricting the growth of brain tumour initiating cells."
The drug they identified is a powerful agent that is already used clinically to treat severe fungal infections of the brain and spinal cord. "It's a rather harsh medication," says Yong. "But we have demonstrated that this drug can be used in very small doses where it is not only well tolerated, but it is also effective in re-programming microglia."
Yong and Sarkar hope this discovery will lead to clinical trials and ultimately to a new standard of care for brain tumour patients.
The finding has already garnered attention from researchers across Canada, including internationally recognized brain tumour scientist and neurosurgeon Dr. James Rutka.
"This research is highly significant as it implies that a commercially available drug, amphotericin B, which has never been used before for patients with gliomas, may be a novel treatment to consider in future trials of patients with this frequently lethal cancer," says Dr. Rutka, Professor and Chair, Department of Surgery, University of Toronto.
The funding was provided by Alberta Innovates – Health Solutions/Alberta Cancer Foundation. V. Wee Yong is a Canada Research Chair in Neuroimmunology.
Marta | EurekAlert!
Researchers find new potential approach to type 2 diabetes treatment
11.11.2019 | Weill Cornell Medicine
Why beta-blockers cause skin inflammation
07.11.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn
Carbon nanotubes (CNTs) are valuable for a wide variety of applications. Made of graphene sheets rolled into tubes 10,000 times smaller than a human hair, CNTs have an exceptional strength-to-mass ratio and excellent thermal and electrical properties. These features make them ideal for a range of applications, including supercapacitors, interconnects, adhesives, particle trapping and structural color.
New research reveals even more potential for CNTs: as a coating, they can both repel and hold water in place, a useful property for applications like printing,...
Magnetische Nanostrukturen maßgeschneidert herzustellen und nanomagnetische Materialeigenschaften gezielt zu beeinflussen, daran arbeiten Physiker des Helmholtz-Zentrums Dresden-Rossendorf (HZDR) gemeinsam mit Kollegen des Leibniz-Instituts für Festkörper- und Werkstoffforschung (IFW) Dresden und der Universität Glasgow. Zum Einsatz kommt ein spezielles Mikroskop am Ionenstrahlzentrum des HZDR, dessen hauchdünner Strahl aus schnellen geladenen Atomen (Ionen) periodisch angeordnete und stabile Nanomagnete in einem Probenmaterial erzeugen kann. Es dient aber auch dazu, die magnetischen Eigenschaften von Kohlenstoff-Nanoröhrchen zu optimieren.
„Materialien im Nanometerbereich magnetisch zu tunen birgt ein großes Potenzial für die Herstellung modernster elektronischer Bauteile. Für unsere magnetischen...
If you've ever tried to put several really strong, small cube magnets right next to each other on a magnetic board, you'll know that you just can't do it. What happens is that the magnets always arrange themselves in a column sticking out vertically from the magnetic board. Moreover, it's almost impossible to join several rows of these magnets together to form a flat surface. That's because magnets are dipolar. Equal poles repel each other, with the north pole of one magnet always attaching itself to the south pole of another and vice versa. This explains why they form a column with all the magnets aligned the same way.
Now, scientists at ETH Zurich have managed to create magnetic building blocks in the shape of cubes that - for the first time ever - can be joined together to...
Quantum-based communication and computation technologies promise unprecedented applications, such as unconditionally secure communications, ultra-precise...
Endogene Mechanismen der Geweberegeneration sind ein innovativer Forschungsansatz, um Herzmuskelschäden zu begegnen. Ihnen widmet sich das internationale REANIMA-Projekt, an dem zwölf europäische Forschungszentren beteiligt sind. Das am CNIC (Centro Nacional de Investigaciones Cardiovasculares) in Madrid koordinierte Projekt startet im Januar 2020 und wird von der Europäischen Kommission mit 8 Millionen Euro über fünf Jahre gefördert.
Herz-Kreislauf-Erkrankungen verursachen weltweit die meisten Todesfälle. Herzinsuffizienz ist geradezu eine Epidemie, die neben der persönlichen Belastung mit...
12.11.2019 | Veranstaltungen
11.11.2019 | Veranstaltungen
08.11.2019 | Veranstaltungen
13.11.2019 | Biowissenschaften Chemie
13.11.2019 | Physik Astronomie
13.11.2019 | Biowissenschaften Chemie